No abstract available.
Coronary Disease* ; Secondary Prevention*

China ; Coronary Disease ; prevention & control ; Humans

As an important medical instrument in percutaneous transluminal coronary angioplasty, endovascular stents must have excellent biocompatibility. In this paper, after a description of the performance and fabrication process of stents, we analyzed the technology to improve the biocompatibility of stents during the fabrication process which is the effective method for decreasing the rate of restenosis.
Angioplasty, Balloon, Coronary ; Animals ; Coronary Disease ; therapy ; Coronary Restenosis ; prevention & control ; Humans ; Stents

BACKGROUNDLong-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China.

METHODSIn 2010, standard questionnaires were posted to chief cardiologists in 1397 geographically diverse and representative sample of tertiary and secondary hospitals in China, collecting information about their opinions on the recommended treatments for acute coronary syndrome.

RESULTSA total of 1009 (72%) cardiologists responded with a valid questionnaire. Of them, 77% reported routine use of all the four main secondary preventive treatments, with little difference between secondary and tertiary hospitals (75% vs. 79%, P = 0.16). Of the cardiologists reporting routine or selective use of aspirin, beta-blockers, statins and angiotensin-converting enzyme inhibitors, 94%, 85%, 73% and 86% would recommend indefinite use respectively. For all the 4 treatments combined, only 63.5% reported indefinite use at the same time, with no significant difference between secondary and tertiary hospitals (62% vs. 65%, P = 0.17), nor between hospitals with or without fast track for primary percutaneous coronary intervention (66% vs. 61%, P = 0.50).

CONCLUSIONSAlthough Chinese cardiologists seem well informed about the value of main secondary preventive treatments for acute coronary syndrome, there is still gap in their understanding of the need for combined and prolonged use of these treatments.

Acute Coronary Syndrome ; prevention & control ; China ; Coronary Disease ; prevention & control ; Humans ; Physicians ; statistics & numerical data ; Secondary Prevention ; methods ; Surveys and Questionnaires

Colchicine/therapeutic use* ; Coronary Artery Disease ; Coronary Disease/prevention & control* ; Humans ; Plaque, Atherosclerotic

Behavior Therapy ; Coronary Disease ; prevention & control ; Humans ; Smoking Cessation

Anticoagulants ; therapeutic use ; Coronary Artery Disease ; prevention & control ; Humans

Humans ; Coronary Disease/prevention & control* ; Consensus ; Asian People ; Neoplasms ; China

Coronary heart disease is a kind of heart disease that is caused by atherosclerosis. The lipid deposition in the vessel wall results in occlusion of coronary artery and stenosis, which could induce myocardial ischemia and oxygen deficiency. Intervention therapies like percutaneous coronary intervention (PCI) and coronary stent improve myocardial perfusion using catheter angioplasty to reduce stenosis and occlusion of coronary artery lumen. Accordingly, intervention therapies are widely applied in clinic to treat ischemic cardiovascular disease, arterial intima hyperplasia and other heart diseases, which could save the patients' life rapidly and effectively. However, these interventions also damage the original endothelium, promote acute and subacute thrombosis and intimal hyperplasia, and thus induce in-stent restenosis (ISR) eventually. Studies indicated that the rapid reendothelialization of damaged section determined postoperative effects. In this review, reendothelialization of implants after intervention therapy is discussed, including the resource of cells contributed on injured artery, the influences of implanted stents on hemodynamic, and the effects of damaged degree on reendothelialization.
Angioplasty, Balloon, Coronary ; Cardiac Catheterization ; Coronary Artery Disease ; therapy ; Coronary Restenosis ; prevention & control ; Endothelium, Vascular ; pathology ; Humans ; Myocardial Ischemia ; prevention & control ; Stents ; Thrombosis ; prevention & control

Coronary Disease ; prevention & control ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; therapeutic use ; Primary Prevention ; methods